Drug Profile
Testosterone undecanoate oral - TesoRx
Alternative Names: Low-T therapy - TesoRx; Oral TRT therapy - TesoRx; Testosterone replacement therapy - TesoRx; THG 1001; TSX-011; TSX-049Latest Information Update: 17 Sep 2021
Price :
$50
*
At a glance
- Originator TesoRx
- Developer ASKA Pharmaceutical; TesoRx
- Class Anabolic steroids; Androstenols; Hormonal replacements; Small molecules; Testosterone congeners
- Mechanism of Action Androgen receptor agonists; Testosterone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Hypogonadism
Most Recent Events
- 21 Oct 2020 Preclinical trials in Hypogonadism (TSX 049) in USA (PO) (TesoRx pipeline, October 2020)
- 21 Oct 2020 NDR batch#17: Updated intro, dev table, added FET for planned P-I/II for TSX-049 [discontinued P-I/II trial for TSX 011 as it was terminated and candidate does not appear in company pipeline; added preclinical dev line for TSX 049 on the basis of pipeline]
- 24 Sep 2020 Pharmacokinetics data from a preclinical study in canines for Hypogonadism released by TesoRx